NCT00322296View on ClinicalTrials.gov

Phase II Trial to Evaluate the Efficacy of Topical Bexarotene Gel in Patients With Parapsoriasis

PHASE2TerminatedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

April 30, 2001

Primary Completion Date

July 31, 2004

Study Completion Date

August 31, 2004

Conditions

Parapsoriasis

Interventions

DRUG

Bexarotene 1% gel

Trial Locations (1)

19111

Fox Chase Cancer Center, Philadelphia

Sponsors

Collaborators (1)

Ligand Pharmaceuticals

All Listed Sponsors

collaborator

Ligand Pharmaceuticals

INDUSTRY

lead

Fox Chase Cancer Center

OTHER

NCT00322296 - Phase II Trial to Evaluate the Efficacy of Topical Bexarotene Gel in Patients With Parapsoriasis | Biotech Hunter | Biotech Hunter